| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/03/2004 | WO2004046332A2 Amplified genes involved in cancer |
| 06/03/2004 | WO2004046331A2 2’-branched nucleosides and flaviviridae mutation |
| 06/03/2004 | WO2004046327A2 Inhibitory oliogonucleotides targeted to bcl-2 |
| 06/03/2004 | WO2004046326A2 Modulation of interleukin 22 receptor expression |
| 06/03/2004 | WO2004046325A2 Modulation of serine/threonine kinase 16 expression |
| 06/03/2004 | WO2004046324A2 Allele-targeted rna interference |
| 06/03/2004 | WO2004046317A2 Products and processes for modulating peptide-peptide binding domain interactions |
| 06/03/2004 | WO2004046310A2 Novel mouse polypeptides encoded by polynucleotides and methods of their use |
| 06/03/2004 | WO2004046309A2 Methods for inhibiting viral replication in vivo |
| 06/03/2004 | WO2004046196A2 Compositions and methods for treating bacterial infections with protein-dalbavancin complexes |
| 06/03/2004 | WO2004046182A2 Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases |
| 06/03/2004 | WO2004046180A2 Chemosensitization by a non-apoptogenic heat shock protein 70-binding apoptosis inducing factor mutant add70 |
| 06/03/2004 | WO2004046178A2 Shrew paralytic peptide for use in neuromuscular therapy |
| 06/03/2004 | WO2004046173A1 Scaffolds useful to the synthesis of compounds with biological activity |
| 06/03/2004 | WO2004046172A1 Perindopril |
| 06/03/2004 | WO2004046171A1 Novel functional peptide nucleic acid and process for producing the same |
| 06/03/2004 | WO2004046170A2 Tubulysins, method for producing the same and tubulysin preparations |
| 06/03/2004 | WO2004046169A2 Activation of peptide prodrugs by hk2 |
| 06/03/2004 | WO2004046167A2 Synthesis and self-assembly of abc triblock bola peptide |
| 06/03/2004 | WO2004046166A2 Modified alpha-msh peptides and derivatives thereof |
| 06/03/2004 | WO2004046165A2 Treatment of ophthalmic conditions with kpv and kpv dimers |
| 06/03/2004 | WO2004046070A2 Modulation of proteins by phenolic compoudns |
| 06/03/2004 | WO2004045667A1 Collagen-based materials and methods for treating synovial joints |
| 06/03/2004 | WO2004045648A1 Positional isomers of peg ifn alpha 2a |
| 06/03/2004 | WO2004045640A1 Gastrin compositions and formulations, and methods of use and preparation |
| 06/03/2004 | WO2004045638A1 Vanilloid receptor-2 ligands for treating anxiety or depression |
| 06/03/2004 | WO2004045637A1 Dalbavancin compositions for treatment of bacterial infections |
| 06/03/2004 | WO2004045636A1 Methods of administering dalbavancin for treatment of bacterial infections |
| 06/03/2004 | WO2004045635A1 Muslce building preparation |
| 06/03/2004 | WO2004045634A1 Composition and method for treating inflammatory diseases using protease inhibitors |
| 06/03/2004 | WO2004045594A1 Agent for dissolving dental calculi and dental caries |
| 06/03/2004 | WO2004045593A2 Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| 06/03/2004 | WO2004045592A2 Compounds and methods for increasing neurogenesis |
| 06/03/2004 | WO2004045563A2 Method of treatment of myocardial infarction |
| 06/03/2004 | WO2004045555A2 Immunogenic epitopes for fibroblast growth factor 5 (fgf-5) presented by hla-a3 and hla-a2 |
| 06/03/2004 | WO2004045554A2 Cytomodulating peptides for treating interstitial cystitis |
| 06/03/2004 | WO2004045550A2 Immunization with porphyromonas gingivalis protects against heart disease |
| 06/03/2004 | WO2004045544A2 Autocrine growth factor receptor antibodies and methods |
| 06/03/2004 | WO2004045542A2 Therapeutic bioconjugates |
| 06/03/2004 | WO2004045535A2 Molecular interactions in neurons |
| 06/03/2004 | WO2004045532A2 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 06/03/2004 | WO2004045531A2 Protection of cardiac myocardium |
| 06/03/2004 | WO2004045530A2 Methods for treating, preventing, or reducing cardiac disorders using fadd inhibitors |
| 06/03/2004 | WO2004045527A2 Modulation of nima-related kinase 6 expression |
| 06/03/2004 | WO2004045520A2 Complement receptor 2 targeted complement modulators |
| 06/03/2004 | WO2004045519A2 Induction of apoptosis by hiv-1 infected monocytic cells |
| 06/03/2004 | WO2004045516A2 Compositions and methods for the diagnosis and treatment of tumor |
| 06/03/2004 | WO2004045499A2 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 06/03/2004 | WO2004045497A2 Cd26-based therapies for cancers and immune disease |
| 06/03/2004 | WO2004045496A2 Compositions and devices comprising or encoding the run x2 protein and method of use |
| 06/03/2004 | WO2004045392A2 Diagnostic method for celiac sprue |
| 06/03/2004 | WO2004045376A2 Screening methods to identify treatments for autoimmune disease |
| 06/03/2004 | WO2004035623A3 Stabilized exendin-4 compounds |
| 06/03/2004 | WO2004035615A3 Factor involved in metastasis and uses thereof |
| 06/03/2004 | WO2004033723A3 Neurodegenerative disease-associated gene |
| 06/03/2004 | WO2004029215A9 Conditional gene expression using rnai |
| 06/03/2004 | WO2004027033A3 Lentiviral vector-mediated gene transfer and uses thereof |
| 06/03/2004 | WO2004025416A3 Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby |
| 06/03/2004 | WO2004024198A8 Activator for forming platelet gel, platelet poor plasma gel or platelet rich plasma gel |
| 06/03/2004 | WO2004022708A3 Genes and proteins altering tau-related neurodegeneration |
| 06/03/2004 | WO2004022103A3 Foxp1 and uses thereof |
| 06/03/2004 | WO2004020451A9 Group b streptococcal phage lysin |
| 06/03/2004 | WO2004018515A3 T-cell epitopes in erythropoietin |
| 06/03/2004 | WO2004013306A3 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 06/03/2004 | WO2004012759A3 Use of erythropoietin |
| 06/03/2004 | WO2004009021A3 Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same |
| 06/03/2004 | WO2004007725A9 Polypeptide of streptococcus pyogenes |
| 06/03/2004 | WO2004006830A3 Use of ccn protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux |
| 06/03/2004 | WO2004002513A3 Proteins involved in the regulation of energy homeostasis |
| 06/03/2004 | WO2004002415A9 Compositions and methods for modulating a cytotoxic t lymphocyte immune response |
| 06/03/2004 | WO2003103697A3 Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity |
| 06/03/2004 | WO2003103611A3 Methods and compositions for the repair and/or regeneration of damaged myocardium |
| 06/03/2004 | WO2003103595A3 Androgen receptor coregulators |
| 06/03/2004 | WO2003100432A3 Method for identifying immunoreactive peptides |
| 06/03/2004 | WO2003100024A3 Treatment for diabetes |
| 06/03/2004 | WO2003099194A3 Pharmaceutical combination of pde5 inhibitors with ace inhibitors |
| 06/03/2004 | WO2003096022A8 Screening for peptides inhibiting pp1c binding to bcl-2, bcl-xl and bcl-w proteins |
| 06/03/2004 | WO2003093476A9 Vector with modified protease-dependent tropism |
| 06/03/2004 | WO2003092595A3 Tyrosine kinase inhibitors |
| 06/03/2004 | WO2003091275A3 Compositions containing anti-hiv peptides and methods of use |
| 06/03/2004 | WO2003089450A3 Fusion polypeptides and methods for inhibiting microbial adhesion |
| 06/03/2004 | WO2003070972A3 RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 06/03/2004 | WO2003061680A9 Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease |
| 06/03/2004 | WO2003059245A3 Method of treating asthma |
| 06/03/2004 | WO2003041128A3 Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells |
| 06/03/2004 | WO2003024481A3 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| 06/03/2004 | WO2003018610A8 Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods |
| 06/03/2004 | WO2003016567A3 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 06/03/2004 | WO2003015706A3 Borinic acid protease inhibitors |
| 06/03/2004 | WO2003006104A8 Lymphatic endothelial cells materials and methods |
| 06/03/2004 | WO2003000928A3 Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof |
| 06/03/2004 | WO2002102846B1 Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state |
| 06/03/2004 | WO2002097108A3 Antisense modulation of dual specific phosphatase 5 expression |
| 06/03/2004 | WO2002093998A3 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| 06/03/2004 | WO2002088312A3 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 06/03/2004 | WO2002079402A9 Method of inhibiting cancerous cell proliferation using ras mutants of gdp-bound conformation |
| 06/03/2004 | WO2002073188A9 Method for generating replacement cells and/or tissues |
| 06/03/2004 | WO2002064739A3 A cytokine related structurally to il-17 |
| 06/03/2004 | WO1997035010A8 Chemokine alpha 2 |
| 06/03/2004 | US20040107434 Customized media method and system |